Trials / Completed
CompletedNCT01150903
Identification of Underlying Conditions in Men Prescribed a PDE5 Inhibitor
Prevalence and Incidence of Underlying Disease Diagnosed in Men With Erectile Dysfunction When Prescribed a PDE5i for the First Time
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 98,832 (actual)
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Erectile dysfunction (ED) has been identified as an independent risk factor for existing cardiovascular disease, preceding a major cardiovascular event by an average of about 5 years. Are men prescribed a PDE5 inhibitor for ED more likely to have a new diagnosis of underlying medical conditions compared to men of a similar age not receiving PDE5 inhibitor treatment?
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | no intervention | non-interventional study |
| OTHER | no intervention | non-interventional study |
Timeline
- Start date
- 2010-05-01
- Primary completion
- 2010-07-01
- Completion
- 2010-08-01
- First posted
- 2010-06-25
- Last updated
- 2021-07-19
- Results posted
- 2012-05-11
Source: ClinicalTrials.gov record NCT01150903. Inclusion in this directory is not an endorsement.